ArticleCancer2026

A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Kathy D Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.